Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Article
CAS
PubMed
Google Scholar
Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984–96.
Article
PubMed
Google Scholar
Grossman SA, Norris LK. Adjuvant and neoadjuvant treatment for primary brain tumors in adults. Semin Oncol. 1995;22:530–9.
CAS
PubMed
Google Scholar
Grossman SA, Batara JF. Current management of glioblastoma multiforme. Semin Oncol. 2004;31:635–44.
Article
CAS
PubMed
Google Scholar
Galanis E, Buckner J. Chemotherapy for high-grade gliomas. Br J Cancer. 2000;82:1371–80.
Article
PubMed Central
CAS
PubMed
Google Scholar
Ewing JR, Brown SL, Lu M, Panda S, Ding G, Knight RA, et al. Model selection in magnetic resonance imaging measurements of vascular permeability: gadomer in a 9 L model of rat cerebral tumor. J Cereb Blood Flow Metab. 2006;26:310–20.
Article
PubMed
Google Scholar
Neuwelt EA, Frenkel EP, D’Agostino AN, Carney DN, Minna JD, Barnett PA, et al. Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood–brain barrier. Cancer Res. 1985;45:2827–33.
CAS
PubMed
Google Scholar
Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood–brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood–brain barrier. Proc Natl Acad Sci U S A. 1982;79:4420–3.
Article
PubMed Central
CAS
PubMed
Google Scholar
Groothuis DR, Fischer JM, Lapin G, Bigner DD, Vick NA. Permeability of different experimental brain tumor models to horseradish peroxidase. J Neuropathol Exp Neurol. 1982;41:164–85.
Article
CAS
PubMed
Google Scholar
Halperin EC, Burger PC, Bullard DE. The fallacy of the localized supratentorial malignant glioma. Int J Radiat Oncol, Biol, Phys. 1988;15:505–9.
Article
CAS
Google Scholar
Barba D, Saris SC, Holder C, Rosenberg SA, Oldfield EH. Intratumoral LAK cell and interleukin–2 therapy of human gliomas. J Neurosurg. 1989;70:175–82.
Article
CAS
PubMed
Google Scholar
Hayes RL, Koslow M, Hiesiger EM, Hymes KB, Hochster HS, Moore EJ, et al. Improved long term survival after intracavitary interleukin–2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer. 1995;76:840–52.
Article
CAS
PubMed
Google Scholar
Kawakami M, Kawakami K, Puri RK. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy. J Neurooncol. 2003;65:15–25.
Article
PubMed
Google Scholar
Weber F, Asher A, Bucholz R, Berger M, Prados M, Chang S, et al. Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol. 2003;64:125–37.
PubMed
Google Scholar
DiMeco F, Rhines LD, Hanes J, Tyler BM, Brat D, Torchiana E, et al. Paracrine delivery of IL-12 against intracranial 9 L gliosarcoma in rats. J Neurosurg. 2000;92:419–27.
Article
CAS
PubMed
Google Scholar
Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64:9160–6.
Article
CAS
PubMed
Google Scholar
Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362–8.
Article
CAS
PubMed
Google Scholar
Holladay FP, Heitz T, Chen YL, Chiga M, Wood GW. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery. 1992;31:528–33.
Article
CAS
PubMed
Google Scholar
Liu Y, Ehtesham M, Samoto K, Wheeler CJ, Thompson RC, Villarreal LP, et al. In situ adenoviral interleukin 12 gene transfer confers potent and long-lasting cytotoxic immunity in glioma. Cancer Gene Ther. 2002;9:9–15.
Article
CAS
PubMed
Google Scholar
Jean WC, Spellman SR, Wallenfriedman MA, Hall WA, Low WC. Interleukin-12-based immunotherapy against rat 9 L glioma. Neurosurgery. 1998;42:850–6. discussion 856–857.
Article
CAS
PubMed
Google Scholar
Salmaggi A, Eoli M, Frigerio S, Silvani A, Gelati M, Corsini E, et al. Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. J Neurooncol. 2003;62:297–303.
Article
PubMed
Google Scholar
Hendrzak JA, Brunda MJ. Antitumor and antimetastatic activity of interleukin-12. Curr Top Microbiol Immunol. 1996;213(Pt 3):65–83.
CAS
PubMed
Google Scholar
Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS. In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin Exp Metastasis. 1996;14:219–29.
CAS
PubMed
Google Scholar
Cohen J. IL-12 deaths: explanation and a puzzle. Sci. 1995;270:908.
Article
CAS
Google Scholar
Gately MK, Warrier RR, Honasoge S, Carvajal DM, Faherty DA, Connaughton SE, et al. Administration of recombinant IL-12 to normal mice enhances cytolytic lymphocyte activity and induces production of IFN-gamma in vivo. Int Immunol. 1994;6:157–67.
Article
CAS
PubMed
Google Scholar
Ohno R, Yamaguchi Y, Toge T, Kinouchi T, Kotake T, Shibata M, et al. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies. Clin Cancer Res. 2000;6:2661–9.
CAS
PubMed
Google Scholar
Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood–brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage. 2005;24:12–20.
Article
PubMed
Google Scholar
Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood–brain barrier in rabbits. Radiol. 2001;220:640–6.
Article
CAS
Google Scholar
Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Non-invasive opening of BBB by focused ultrasound. Acta Neurochir Suppl. 2003;86:555–8.
CAS
PubMed
Google Scholar
Mesiwala AH, Farrell L, Wenzel HJ, Silbergeld DL, Crum LA, Winn HR, et al. High-intensity focused ultrasound selectively disrupts the blood–brain barrier in vivo. Ultrasound Med Biol. 2002;28:389–400.
Article
PubMed
Google Scholar
Neuwelt EA, Howieson J, Frenkel EP, Specht HD, Weigel R, Buchan CG, et al. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood–brain barrier modification in glioblastoma. Neurosurgery. 1986;19:573–82.
Article
CAS
PubMed
Google Scholar
Weber FW, Floeth F, Asher A, Bucholz R, Berger M, Prados M, et al. Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma. Acta Neurochir Suppl. 2003;88:93–103.
CAS
PubMed
Google Scholar
Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy. Technol Cancer Res Treat. 2006;5:239–50.
Article
CAS
PubMed
Google Scholar
Kishima H, Shimizu K, Miyao Y, Mabuchi E, Tamura K, Tamura M, et al. Systemic interleukin 12 displays anti-tumour activity in the mouse central nervous system. Br J Cancer. 1998;78:446–53.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kikuchi T, Joki T, Akasaki Y, Abe T, Ohno T. Antitumor activity of interleukin 12 against interleukin 2-transduced mouse glioma cells. Cancer Lett. 1999;135:47–51.
Article
CAS
PubMed
Google Scholar
Yang SY, Liu H, Zhang JN. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol. 2004;23:381–9.
Article
CAS
PubMed
Google Scholar
Suzuki R, Namai E, Oda Y, Nishiie N, Otake S, Koshima R, et al. Cancer gene therapy by IL-12 gene delivery using liposomal bubbles and tumoral ultrasound exposure. J Control Release. 2010;142:245–50.
Article
CAS
PubMed
Google Scholar
Ren H, Boulikas T, Lundstrom K, Soling A, Warnke PC, Rainov NG. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene–a phase I/II clinical protocol. J Neurooncol. 2003;64:147–54.
CAS
PubMed
Google Scholar
Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004;27:452–9.
Article
CAS
PubMed
Google Scholar
Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, et al. Antitumor activity of interleukin 12 in preclinical models. Cancer Chemother Pharmacol. 1996;38(Suppl):S16–21.
Article
CAS
PubMed
Google Scholar
Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178:1223–30.
Article
CAS
PubMed
Google Scholar
Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol. 1991;147:874–82.
CAS
PubMed
Google Scholar
Naume B, Gately M, Espevik T. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol. 1992;148:2429–36.
CAS
PubMed
Google Scholar
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Sci. 1993;260:547–9.
Article
CAS
Google Scholar
Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170:827–45.
Article
CAS
PubMed
Google Scholar
Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med. 2009;7:5.
Article
PubMed Central
PubMed
Google Scholar
Strasly M, Cavallo F, Geuna M, Mitola S, Colombo MP, Forni G, et al. IL-12 inhibition of endothelial cell functions and angiogenesis depends on lymphocyte-endothelial cell cross-talk. J Immunol. 2001;166:3890–9.
Article
CAS
PubMed
Google Scholar
Bekeredjian R, Kroll RD, Fein E, Tinkov S, Coester C, Winter G, et al. Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol. 2007;33:1592–8.
Article
PubMed
Google Scholar
Ferrara K, Pollard R, Borden M. Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. Annu Rev Biomed Eng. 2007;9:415–47.
Article
CAS
PubMed
Google Scholar
Fischer K, McDannold NJ, Zhang Y, Kardos M, Szabo A, Reusz GS, et al. Renal ultrafiltration changes induced by focused US. Radiol. 2009;253:697–705.
Article
Google Scholar
Stieger SM, Caskey CF, Adamson RH, Qin S, Curry FR, Wisner ER, et al. Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model. Radiol. 2007;243:112–21.
Article
Google Scholar
Miller DL, Song J. Tumor growth reduction and DNA transfer by cavitation-enhanced high-intensity focused ultrasound in vivo. Ultrasound Med Biol. 2003;29:887–93.
Article
PubMed
Google Scholar
Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–43.
Article
PubMed Central
CAS
PubMed
Google Scholar
Shah W, Yan X, Jing L, Zhou Y, Chen H, Wang Y. A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes and a high percentage of CD4 (+) FOXP3 (+) regulatory T cells are significantly associated with clinical outcome in squamous cell carcinoma of the cervix. Cell Mol Immunol. 2011;8:59–66.
Article
PubMed Central
PubMed
Google Scholar